0.6614

6.95% -0.0494

After Hours: .66 -0.0014 -0.21%

Lyell Immunopharma Inc (LYEL)

Overview News Price History Option Chain Financials Discussions Forecast

Lyell Immunopharma Inc stock is traded at $0.6614, with a volume of 652.96K. It is down -6.95% in the last 24 hours and up +13.16% over the past month. Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Previous Close:

$0.7108

Open:

$0.7057

24h Volume:

652.96K

Relative Volume:

0.55

Market Cap:

$192.89M

Revenue:

$54,000

Net Income/Loss:

$-210.26M

P/E Ratio:

-0.8372

EPS:

-0.79

Net Cash Flow:

$-159.01M

1W Performance:

-0.56%

1M Performance:

+13.16%

6M Performance:

-52.76%

1Y Performance:

-78.46%

1-Day Range:

$0.6506

$0.7057

1-Week Range:

$0.6441

$0.7326

52-Week Range:

$0.5092

$3.2556

Lyell Immunopharma Inc Stock (LYEL) Company Profile

Name

Lyell Immunopharma Inc

Sector

Healthcare (1189)

Industry

Biotechnology (682)

Phone

650 695-0677

Address

201 HASKINS WAY, SOUTH SAN FRANCISCO

Employee

224

Twitter

Next Earnings Date

2025-03-03

Latest SEC Filings

LYEL's Discussions on Twitter

Compare LYEL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LYEL Lyell Immunopharma Inc	0.6614	192.89M	54,000	-210.26M	-159.01M	-0.79
VRTX Vertex Pharmaceuticals Inc	483.31	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	684.87	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	622.61	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	243.53	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	111.56	27.34B	3.30B	-501.07M	1.03B	-2.1146

Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-30-24	Downgrade	BofA Securities	Buy → Underperform
Jun-27-24	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral
Nov-14-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-11-22	Downgrade	Goldman	Buy → Neutral
Oct-17-22	Initiated	H.C. Wainwright	Buy
Jul-12-21	Initiated	BofA Securities	Buy
Jul-12-21	Initiated	Goldman	Buy
Jul-12-21	Initiated	JP Morgan	Overweight
Jul-12-21	Initiated	Morgan Stanley	Overweight

View All

Lyell Immunopharma Inc Stock (LYEL) Latest News

Feb 20, 2025

Lyell Immunopharma (LYEL) Projected to Post Earnings on Wednesday - MarketBeat

Feb 20, 2025

Feb 19, 2025

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences - GlobeNewswire

Feb 19, 2025

Feb 18, 2025

LYELLyell Immunopharma, Inc. Latest Stock News & Market Updates - StockTitan

Feb 18, 2025

Cell Therapy Pioneer Lyell to Showcase Cancer Treatment Breakthroughs at Elite Investor Events - StockTitan

Feb 18, 2025

What Did We Find About Insider Trading At Lyell Immunopharma Inc (NASDAQ: LYEL)? - Stocks Register

Feb 18, 2025

Feb 17, 2025

Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why - MSN

Feb 17, 2025

Following a 67% decline over last year, recent gains may please Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional owners - Simply Wall St

Feb 17, 2025

Feb 14, 2025

SG Americas Securities LLC Has $75,000 Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

Feb 14, 2025

Feb 10, 2025

Market Recap Check: Lyell Immunopharma Inc (LYEL)’s Negative Finish at 0.57, Up/Down -2.94 - The Dwinnex

Feb 10, 2025

Feb 07, 2025